Camrelizumab (anti-PD-1 inhibitor)

DRUG4 trials

Sponsors

Shanghai Jiao Tong University School of Medicine, Sun Yat-sen University, Henan Cancer Hospital, The First Affiliated Hospital of Henan University of Science and Technology

Conditions

Anti-PD-1Anti-VEGFRHCC - Hepatocellular CarcinomaHepatocellulcar CarcinomaLate-stage Resectable Esophageal Squamous CarcinomaNeoadjvant TherapyOral Squamous Cell Carcinoma

Phase 2

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

RecruitingNCT05069857

Shanghai Jiao Tong University School of MedicineAnti-PD-1, Anti-VEGFR, Neoadjvant Therapy +1

Start: 2021-09-01End: 2028-06-30Target: 46Updated: 2023-11-22

Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment

RecruitingNCT07238881

Sun Yat-sen UniversityHepatocellulcar Carcinoma

Start: 2025-11-05End: 2027-06-01Target: 30Updated: 2025-11-20

Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

RecruitingNCT07622797

The First Affiliated Hospital of Henan University of Science and TechnologyLate-stage Resectable Esophageal Squamous Carcinoma

Start: 2025-11-21End: 2030-12-31Target: 164Updated: 2026-06-03

Unknown Phase

A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors

Not yet recruitingNCT07618546

Henan Cancer HospitalHCC - Hepatocellular Carcinoma

Start: 2026-05-25End: 2028-03-31Target: 208Updated: 2026-06-01

Related Papers

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

Nature Communications2022-09-14110 citations